文献速递神经肿瘤

散发性视路胶质瘤放疗后长期视力结局

Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma.
PubMed 文献 · J Neurooncol · 2019-08-14

本研究回顾1997至2017年41例接受放疗的散发性视路胶质瘤患儿,分析其长期视力结局。中位随访5年,较差眼5年视力下降累积发生率为17.9%,较好眼为11.5%;视力下降多发生于放疗后前2年内,且与影像学肿瘤进展无关。

要点

  • 放疗后5年视力下降累积发生率较低,较差眼17.9%、较好眼11.5%。
  • 视力下降最可能发生在放疗后前2年内,需加强眼科监测。
  • 视力结局与影像学肿瘤进展无相关性。

核心结论

  • 放疗后5年视力下降累积发生率较低。
  • 视力下降最可能发生于放疗后前2年内,且与影像学疾病进展无关。

研究设计与样本

  • 回顾性队列研究,纳入1997至2017年41例接受放疗且基线视力测试的散发性视路胶质瘤患者。
  • 所有患者放疗后前5年每3-6个月进行系列视力测试,此后每年测试。
  • 采用死亡作为竞争风险估算每眼视力下降或改善的累积发生率。

主要发现

  • 平均随访5年,93%肿瘤累及交叉后视束和/或下丘脑。
  • 15例检测BRAF改变,其中67%存在BRAF融合。
  • 较差眼视力下降中位时间20个月,较好眼22个月。
  • 较差眼5年视力下降和改善累积发生率分别为17.9%(95%CI 7-32.8%)和13.5%(95%CI 4.7-26.7%)。
  • 较好眼5年视力下降和改善累积发生率分别为11.5%(95%CI 3.5-30.7%)和10.6%(95%CI 2.6-25.2%)。

临床怎么用

  • 放疗后前2年应加强眼科检查频率以监测视力变化。
  • 视力下降不应单独作为肿瘤进展的指标,需结合影像学评估。

局限性

  • 样本量较小(41例)。
  • 仅15例进行了BRAF改变检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Children with sporadic optic pathway glioma (OPG) commonly experience a decline in visual acuity (VA). This study aimed to quantify long-term VA outcomes after definitive radiation therapy (RT). METHODS: From 1997 to 2017, 41 patients underwent RT for OPG and had baseline VA testing. All patients underwent serial VA testing every 3-6 months during the first 5 years and annually thereafter. The cumulative incidence of VA decline or improvement (per eye) was estimated using death as a competing risk. RESULTS: Mean follow-up was 5 years. Most tumors (93%) involved the postchiasmatic optic tracts and/or hypothalamus. Of the tumors tested for BRAF alterations (n = 15), 67% had a BRAF fusion. Median time to VA decline was 20 months in the eye with worse vision and 22 months in the better eye. For the worse eye, the 5-year cumulative incidences of VA decline and improvement were 17.9% [95% confidence interval (CI) 7-32.8%] and 13.5% (95% CI 4.7-26.7%), respectively. For the better eye, the 5-year cumulative incidences of VA decline and improvement were 11.5% (95% CI 3.5-30.7%) and 10.6% (95% CI 2.6-25.2%), respectively. Visual outcomes did not correlate with radiographic evidence of tumor progression. CONCLUSIONS: The 5-year cumulative incidence of VA decline was low. VA decline is most likely to occur within the first 2 years after RT and is not associated with radiographic progression of disease, highlighting the need for frequent ophthalmologic exams during this period.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Acharya S, Quesada S, Coca K, et al. Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma. J Neurooncol. 2019. PMID: 31414376. doi:10.1007/s11060-019-03264-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。